DJNJ3 Stock Overview
Researches, develops, manufactures, and sells various products in the healthcare field worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 6/6 |
Johnson & Johnson Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,250.00 |
| 52 Week High | US$1,575.00 |
| 52 Week Low | US$602.00 |
| Beta | 0.55 |
| 1 Month Change | 7.02% |
| 3 Month Change | -6.72% |
| 1 Year Change | n/a |
| 3 Year Change | 453.10% |
| 5 Year Change | n/a |
| Change since IPO | 613.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| DJNJ3 | AR Pharmaceuticals | AR Market | |
|---|---|---|---|
| 7D | 3.3% | -0.9% | 10.6% |
| 1Y | n/a | -16.2% | 350.0% |
Return vs Industry: Insufficient data to determine how DJNJ3 performed against the AR Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how DJNJ3 performed against the AR Market.
Price Volatility
| DJNJ3 volatility | |
|---|---|
| DJNJ3 Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AR Market | 12.1% |
| 10% least volatile stocks in AR Market | 6.9% |
Stable Share Price: DJNJ3 has not had significant price volatility in the past 3 months.
Volatility Over Time: DJNJ3's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 131,900 | Joaquin Duato | www.jnj.com |
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke.
Johnson & Johnson Fundamentals Summary
| DJNJ3 fundamental statistics | |
|---|---|
| Market cap | AR$323.81t |
| Earnings (TTM) | AR$15.19t |
| Revenue (TTM) | AR$76.19t |
21.6x
P/E Ratio4.3x
P/S RatioIs DJNJ3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DJNJ3 income statement (TTM) | |
|---|---|
| Revenue | US$85.65b |
| Cost of Revenue | US$26.26b |
| Gross Profit | US$59.39b |
| Other Expenses | US$42.32b |
| Earnings | US$17.07b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 17, 2024
| Earnings per share (EPS) | 7.09 |
| Gross Margin | 69.34% |
| Net Profit Margin | 19.93% |
| Debt/Equity Ratio | 48.0% |
How did DJNJ3 perform over the long term?
See historical performance and comparison